Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

News Release

Greenlink International announces launch of Suncliff CBD-infused pillow

Greenlink International

Greenlink International CEO Jake George joined Steve Darling from Proactive to share news the company has launched its Suncliff CBD-infused pillow in collaboration with Purecare. George tells Proactive this unique collection features five luxury pillows that incorporate microencapsulated CBD in the fabric, along with a complementary lavender CBD bedding mist to create what they say is a soothing sleep environment. The pillow will be available online and select retail locations in the US in May 2023. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

May 04, 2023 12:42 PM Eastern Daylight Time

Video

CleverTap appoints Benjamin Roodman as Vice President, Partnerships, North America

CleverTap

CleverTap, the all-in-one engagement platform, named Benjamin Roodman as Vice President, Partnerships for North America. In his new role, Benjamin will lead CleverTap’s channel and technical partner strategy – developing and managing relationships to drive CleverTap’s growth within the region. With over two decades of experience across the board, Benjamin has spent the past 13 years strengthening relations with business and channel partners. His appointment will help CleverTap build a more fruitful partner ecosystem within North America and further cement their position as market leaders in the region. Benjamin joins CleverTap from AppsFlyer where he was the AVP of Business Development. In his previous roles he has led partnerships across mobile SaaS, digital advertising, and cloud platforms. He is well versed in mobile growth platforms with a notable aptitude for analytics. “We are thrilled to have Benjamin on board. With the wealth of knowledge and experience he brings to the team, he will help drive growth in North America – a key-market for us.” said Momchil Kyurkchiev, Chief Strategy Officer at CleverTap. “Our channel and technical partners are an integral part of our growth strategy. To establish a robust partner ecosystem, it is crucial to collaborate with them and incorporate tools that offer innovative solutions to unanticipated issues. I am confident that with Benjamin’s appointment we will continue to build a world-class partner ecosystem and drive value for our customers.” “I am ecstatic to embark on this new journey and make a measured impact with CleverTap. A strong foundation in North America, and a burgeoning partner ecosystem, are a testament of CleverTap’s commitment within the region. At CleverTap, we understand the importance of building a robust partner network to further penetrate markets and provide exceptional service to our customers.” said Benjamin. “I look forward to working closely with our partners to develop innovative solutions that meet the evolving needs of our customers and accelerate their success. Together we will continue to drive innovation, foster collaboration, and build a stronger base for our expansion.” About CleverTap CleverTap is the all-in-one customer engagement platform that helps brands personalize and optimize all consumer touch points to improve user engagement, retention, and lifetime value. It's the only solution built to address the needs of retention and growth teams, with audience analytics, deep-segmentation, multi-channel engagement, product recommendations, and automation in one unified product. The platform is powered by TesseractDB™ – the world’s first purpose-built database for customer engagement, offering both speed and economies of scale. CleverTap is trusted by 2000 customers, including Electronic Arts, TiltingPoint, Gamebasics, Big Fish, MobilityWare, TED, English Premier League, TD Bank, Carousell, AirAsia, Papa John’s, and Tesco. Backed by leading investors such as Sequoia India, Tiger Global, Accel, and CDPQ the company is headquartered in Mountain View, California, with presence in San Francisco, New York, São Paulo, Bogota, London, Amsterdam, Sofia, Dubai, Mumbai, Singapore, and Jakarta. For more information, visit clevertap.com or follow on LinkedIn and Twitter. Forward-Looking Statements Some of the statements in this press release may represent CleverTap's belief in connection with future events and may be forward-looking statements, or statements of future expectations based on currently available information. CleverTap cautions that such statements are naturally subject to risks and uncertainties that could result in the actual outcome being absolutely different from the results anticipated by the statements mentioned in the press release. Factors such as the development of general economic conditions affecting our business, future market conditions, our ability to maintain cost advantages, uncertainty with respect to earnings, corporate actions, client concentration, reduced demand, liability or damages in our service contracts, unusual catastrophic loss events, war, political instability, changes in government policies or laws, legal restrictions impacting our business, impact of pandemic, epidemic, any natural calamity and other factors that are naturally beyond our control, changes in the capital markets and other circumstances may cause the actual events or results to be materially different, from those anticipated by such statements. CleverTap does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated or revised status of such statements. Therefore, in no case whatsoever will CleverTap and its affiliate companies be liable to anyone for any decision made or action taken in conjunction. Contact Details Sony Shetty sony@clevertap.com Company Website https://clevertap.com/

May 04, 2023 07:00 AM Pacific Daylight Time

Emergent Health to spin out subsidiary PharmaZu to its Shareholders pursuant to an IPO underwritten by a Nationally Recognized Investment Banking Firm

Emergent Health Corp.

Emergent Health Corp. (OTC: EMGE), a curator, developer, and marketer of products in the Regenerative Health Space announced today that it has executed a Term Sheet for a firm committed underwriting with a nationally recognized investment banking firm for $10,000,000 with respect to planned corporate financing transactions, including the private placement of securities (“pre-IPO Financings”) and the planned $10 million initial public offering of Emergent subsidiary PharmaZu common stock (“IPO”) that will be applied for listing on NASDAQ or NYSE/AMEX, with NO DILUTION to Emergent shareholders. PharmaZu is a pure play, e-commerce products and service provider focused on the Pet Community, Pet Pharmacy and Pet Wellness using Influencers and their content, including pet pharmacy, vet telehealth and pet wellness businesses. Upon the effectiveness of the IPO and listing on a national exchange, PharmaZu plans to acquire a 48-state authorized compounding pharmacy located in West Palm Beach, FL, doing approximately $10M a year in revenue, which will serve as the backbone and fulfilment center for PharmaZu, creating a national platform throughout the United States. Subsequently, Emergent plans to distribute to its shareholders, pro rata, the shares of PharmaZu as a dividend, when a record date is set. The raise of capital will be used for expanding PharmaZu’s business, product offerings, as well as for acquisitions. Jim Morrison, former L'Oréal President and Emergents full time CEO stated, “The transaction with Boustead will start a new exciting chapter for PharmaZu, while maximizing the value to Emergent’s shareholders.” Adam Books, President of PharmaZu stated, “PharmaZu is poised to start its disrupting of the mail order pet business and pet medications, as well as advancing the tele-pet med environment. I am very thrilled to be a part of this.” The execution of the Engagement Letter does not constitute a commitment by Boustead or the Company to consummate any transaction contemplated hereunder and does not ensure the successful placement of securities of any investment vehicle or the success of Boustead with respect to finding any investors or the success with respect to any transaction. No promises, representations or guarantees have been made. ABOUT EMERGENT HEALTH CORPORATION Emergent curates, develops and sells products in the Regenerative Health Space. Its products comprise of ingestibles as well as topicals for the whole family. The company distributes its products online and through Content Based Shopping using Influencers to position products in their produced content throughout the United States and Internationally. Its subsidiaries; PharmaZu, is a pure play, e-commerce products and service provider focused on the Pet Community, Pet Pharmacy and Pet Wellness using Influencers and their content, including the pet pharmacy, vet telehealth and pet wellness businesses; Regen BioWellness, is a distributor of various products in the plant-based and regenerative medical fields. Evolutionary Biologics, is a new kind of biologics company founded for a clear purpose: bring cutting edge regenerative products to the medical community. Emergent does not claim any of its products are approved by the FDA to diagnose, treat, cure or prevent any disease. For more information, please visit Emergent's Website and Social Media on Twitter. Before using any products, you should always consult with your Veterinarian and/or Family Doctor. SAFE HARBOR STATEMENT This press release contains forward-looking statements that can be identified by terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company's control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made. FOR MORE INFORMATION, PLEASE CONTACT: Jim Morrison, CEO Emergent Health Corporation Website info@emergenthealthcompany.com Contact Details Emergent Health Corp. info@emergenthealthcompany.com Company Website https://emergenthealthcompany.com/

May 04, 2023 09:00 AM Eastern Daylight Time

Image

Hong Kong Baptist University joint research suggests that urine cytomegalovirus test facilitates early prediction of AIDS end-organ diseases

Hong Kong Baptist University

HONG KONG SAR - Media OutReach - 4 May 2023 - A Hong Kong Baptist University (HKBU) collaborative research team has shown that urine tests for human cytomegalovirus (HCMV) can identify the risk of end-organ diseases such as pneumonitis, gastrointestinal ulcers, hepatitis and myocarditis, earlier in patients who have been infected with human immunodeficiency virus type 1 (HIV-1). The findings suggest that HCMV detection in urine should be implemented as a routine test for HIV-1 patients who are progressing towards acquired immunodeficiency syndrome (AIDS), as anti-HCMV treatments could reduce the incidence of lung and cardiovascular end-organ diseases by half. The research findings have been published in the Journal of Clinical Virology, an international scientific journal. No routine HCMV check-ups for HIV-1 patients HIV-1 infection is divided into four clinical stages. In the first stage, patients are infected and some experience mild illnesses such as a cold without any apparent symptoms. HIV-1 infection then slowly progresses towards AIDS in the second and third stages of infection. These two stages, collectively regarded as the "developing" stage, usually last several years if they are comprehensively controlled by a range of medications before developing into AIDS, which represents the fourth stage of HIV-1 infection. HCMV is a DNA virus found in more than half of the human population. It is controlled by an intact immune system and remains dormant in healthy individuals. However, it can be reactivated in patients with poor immune systems, such as those in the fourth stage of HIV-1 infection, and as a result it can become one of the major opportunistic infections that cause life-threatening end-organ diseases. In Hong Kong, HCMV detection is not part of the routine check-ups for HIV-1 patients unless they suffer from apparent end-organ diseases. In such cases, blood tests are the preferred method of detection. A research team co-led by Dr Allen Cheung Ka-loon, Assistant Professor of the Department of Biology at HKBU, and Professor Chen Zhiwei, Professor of the Department of Microbiology, LKS Faculty of Medicine at the University of Hong Kong, in collaboration with researchers from the Third People's Hospital of Shenzhen, investigated the detection of HCMV in urine for the continuous monitoring of end-organ disease risk in HIV-1 patients. They also examined the relationship between HCMV detection and end-organ diseases in HIV-1 patients in the "developing" stage. Easier to detect HCMV in urine than in blood The team screened the records of more than 130,000 HIV-1 patients in Shenzhen between January 2011 and June 2022, and selected about 13,700 patients with relevant blood and urine test records. They were grouped according to the four stages of HIV-1 infection, and the results of their HCMV blood and urine tests were then compared. It was discovered that in all the four patient groups, the proportions of patients found to be HCMV-positive were higher in the urine samples than in the corresponding blood samples. The situation was particularly obvious for HIV-1 patients in the "developing" stage. Urine tests showed that 5.8% of second-stage HIV-1 patients were HCMV-positive compared to only 0.9% using blood tests. The proportions of third-stage HIV-1 patients found to be HCMV-positive using urine and blood tests were 12.8% and 1.4%, respectively. This suggests that HCMV is more easily detected in urine than in the blood, especially during the "developing" stage of HIV-1 infection. The researchers further filtered 233 "developing" stage HIV-1 patients with detailed clinical and disease records to evaluate the association between HCMV and the onset of different types of end-organ diseases. Statistical analysis revealed that there is a significant association between the incidence of lung and cardiovascular end-organ diseases and the detection of HCMV in urine. Early anti-HCMV treatment lowers the risk of end-organ diseases To study the effect of early interventions with anti-HCMV treatments, the team tracked the data of 54 "developing" stage HIV-1 patients who had been hospitalised at least once. They were divided into three groups: those who received no anti-HCMV treatments, those who received treatments but not during each round of hospitalisation, and those who received treatments during all rounds of hospitalisation. The data showed that those who received anti-HCMV treatments in all rounds of hospitalisation had the lowest incidence of lung and cardiovascular end-organ diseases. Furthermore, compared to those who had not received anti-HCMV treatments, the incidence of such end-organ diseases in patients who had received the treatments was reduced by half. This suggests that continuous anti-HCMV treatments are effective in reducing the onset of lung and cardiovascular end-organ diseases in patients who are progressing towards AIDS. Dr Allen Cheung said: "Patients have to face a difficult journey once they have tested positive for HIV. They are often at risk of developing end-organ diseases without any apparent symptoms. Our study shows that routine urine tests for HCMV can monitor the development of end-organ diseases more effectively, which signals the need for early medical intervention. We thus recommend that HCMV detection in urine should be implemented as a routine test for HIV-1 patients." Contact Details Communication and Public Relations Office, HKBU Winnie Shum hkbunews@hkbu.edu.hk

May 04, 2023 09:00 AM Eastern Daylight Time

Image

Doceree Expands Executive Bench with Industry Veterans Marco Parente, Julius Ramirez

Doceree

Doceree, a leading global platform building solutions for healthcare professionals (HCPs) through programmatic messaging with proprietary data tools, has named Marco Parente as EVP Product Management and Julius Ramirez as SVP of Product and Partnership. Parente and Ramirez have joined the U.S. team. The new team members are committed to helping Doceree, which has had robust year-over-year growth, continue its efforts to improve the point-of-care marketing efforts of the pharma industry. “Marco and Julius are talented industry experts who have a deep knowledge of adtech and the role it plays in creating successful campaigns,” said Harshit Jain, global CEO and founder at Doceree. “Their extensive experience with product development and management along with their ability to create lasting global partnerships will support us as we reposition our offerings to deliver the best engagement for our platform partners.” Parente brings more than 20 years of experience in media measurement and market research to his new role in which he is responsible for measurement and identity solutions, product and engineering for Doceree. Prior to joining Doceree, Parente was SVP of product management at Kantar, a leading marketing data and analytics company. He led product partnerships and data integrations for the global media insights business at Kantar. “It is exciting to become a part of Doceree as the company carves new paths for programmatic marketing across the healthcare industry,” Parente said. “The team is dedicated to fostering innovation and leveraging new technologies to improve the industry’s approach to marketing and measurement healthcare, and I’m eager to join Doceree’s transformative efforts.” Ramirez has 25 years of experience in business development and focuses on product and partnership development for Doceree to further strengthen its position as a leading programmatic platform using data, audience targeting, messaging and media planning. Ramirez previously was the head of global partnerships, Meta Audience Network at Meta. There, his focus was on leading strategy and development for the company’s global adtech partnerships. “Doceree has demonstrated tremendous growth through its clear focus on developing solutions to transform healthcare programmatic marketing,“ Ramirez said. “It is amazing to see how Doceree has been able to build a programmatic bridge between healthcare professionals and the pharma industry right when they need it, at the point of care. I am looking forward to helping Doceree to further its efforts to change the way the industry markets to ultimately improve patient care.” About Doceree Doceree is a global platform building unprecedented solutions for healthcare professional (HCP) programmatic messaging with proprietary data tools. It facilitates messaging between life sciences brands and HCPs through an extensive global network of digital endemic and point-of-care platforms to programmatically deliver personalized communications to HCPs and transparent marketing campaign metrics at scale. To learn more, visit doceree.com. Contact Details Kyle Murray +91 70420 89805 kyle@kitehillpr.com Company Website https://doceree.com/us/

May 04, 2023 09:00 AM Eastern Daylight Time

Immunic IMU-856 trial data "clearly goes beyond" initial expectations

Immunic Inc

Immunic Inc (NASDAQ:IMUX) CEO Dr. Daniel Vitt speaks to Thomas Warner from Proactive after releasing new clinical trial data for the biotechnology company's IMU-856 molecule, which is aimed at restoring healthy gut function. The molecule has shown promise in treating celiac disease, with potential applications for other gastrointestinal disorders such as Crohn's disease and ulcerative colitis. Immunic Inc. plans to conduct a Phase 2 clinical trial for IMU-856 in celiac disease patients and explore other potential applications, saying that the phase 1b results "clearly go beyond" initial expectations. Contact Details Proactive United States +1 347-449-0879 action@proactiveinvestors.com

May 04, 2023 08:23 AM Eastern Daylight Time

Video

e-Therapeutics working to capitalise on AI "blindside"

e-Therapeutics PLC

e-Therapeutics PLC (AIM:ETX OTCQX:ETXPF) CEO Ali Mortazavi speaks to Thomas Warner following the release of the computational biology and chemistry company's full year results for 2022. Mortazavi says that it was a "tricky year for the biotechnology sector as a whole" but that eTherapeutics has shown "remarkable resilience." He goes on to highlight the opportunity being presented to the company by the advent of large language models (LLMs) and GPT-4, saying that he's never before seen a technology "blindside the world" to such an extent. Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 04, 2023 08:20 AM Eastern Daylight Time

Video

Creo Medical Group "knows what it needs to do" after "terrific" 2022

Creo Medical Group PLC

Creo Medical Group PLC (AIM:CREO) CEO Craig Gulliford speaks to Thomas Warner from Proactive after releasing full year results for calendar year 2022 - a year he describes as "terrific" for the endoscopy-focused medical device company. Gulliford also gives the highlights from the post-period, which included an oversubscribed £33.7mln gross fundraise in March of 2023, and says Creo "knows what [it] needs to do" moving forward. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 04, 2023 08:05 AM Eastern Daylight Time

Video

Austin-based chief medical officer commits to health equity in Central Texas by joining local American Heart Association Board of Directors

Centre for Neuro Skills

Centre for Neuro Skills (CNS), a leader in brain injury rehabilitation services, and The American Heart Association (AHA), the world’s leading nonprofit organization focused on heart and brain health for all, today announced Dr. Matthew Ashley as a new member of the AHA’s Board of Directors in Central Texas. Dr. Ashley is the chief medical officer for CNS. “I am honored to join the Central Texas American Heart Association board and serve our community by improving heart health and stroke awareness with the AHA,” said Dr. Ashley. “For nearly 100 years, the American Heart Association has been ensuring longer, healthier lives through innovative educational efforts including stroke prevention and treatment. I look forward to our partnership for large-scale community efforts focused on public education and awareness regarding brain injuries.” Earlier this year, the AHA and CNS announced that they are working together to deepen connections with healthcare providers, patients and caregivers while raising awareness of post-stroke care throughout Texas and California. “The Central Texas Board of Directors continues to guide the American Heart Association as we address health disparities throughout our area,” said Sara Harwood, Region Senior Vice President of the American Heart Association. “The addition of Centre for Neuro Skills and Matt Ashley to our Board brings more insight and ideas as we deepen our understanding and ready for action on all aspects of health and well-being.” During Dr. Ashley’s nine-year tenure at CNS, he has served as a consulting neurologist, treating a diverse spectrum of patients recovering from traumatic and acquired brain injury. Dr. Ashley is a noted speaker, who lectures at universities and seminars focusing on stroke, epilepsy, dementia, neuroradiology and brain injury rehabilitation. Dr. Ashley received both his medical and juris doctor degrees from Southern Illinois University. He completed a neurology residency at UCLA, as well as a neurological rehabilitation fellowship at the university’s renowned Neurological Rehabilitation and Research Unit. CNS opened its newest clinic in Austin in June, 2021. The 17,000 square ft. facility can serve 60 patients and is located at 14425 Falconhead Blvd. ### About Centre for Neuro Skills Centre for Neuro Skills is an experienced and respected world leader in providing intensive rehabilitation and medical programs for those recovering from all types of brain injury. CNS covers a full spectrum of advanced care from residential and assisted living to outpatient/day treatment. Founded by Dr. Mark Ashley in 1980, CNS has seven locations in California and Texas. For more information, visit neuroskills.com, Facebook, Twitter, LinkedIn, YouTube. For a video overview of CNS, visit our YouTube channel. About the American Heart Association The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Visit heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1. Contact Details Landis Communications Inc. Robin Carr +1 415-766-0927 cns@landispr.com American Heart Association Megan Jameson +1 512-338-2639 megan.jameson@heart.org Company Website https://www.neuroskills.com/

May 03, 2023 08:32 AM Pacific Daylight Time

Image

1 ... 131 132 133 134 135 ... 310